Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response

Haoyu Zhang; Ke Cao; Ganbin Li; Zhiwei Zhai; Guanghui Wei; Hao Qu; Zhenjun Wang; Jiagang Han

doi:10.3389/fonc.2022.1049228

Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response

Front Oncol. 2022 Nov 10:12:1049228. doi: 10.3389/fonc.2022.1049228. eCollection 2022.

Authors

Haoyu Zhang¹, Ke Cao¹, Ganbin Li¹, Zhiwei Zhai¹, Guanghui Wei¹, Hao Qu¹, Zhenjun Wang¹, Jiagang Han¹

Affiliation

¹ Department of General Surgery, Beijing Chaoyang Hosptial, Capital Medical University, Beijing, China.

Abstract

Aim: To analyze locally advanced rectal cancer (LARC) patients and tumor characteristics during the period of total neoadjuvant therapy (TNT) and explore the risk factors that may predict poor tumor regression in response to TNT.

Materials and methods: The data of 120 LARC patients who received TNT from December 2016 and September 2019 in our hospital were retrospectively analyzed. The clinicopathological characteristics of patients with different tumor regression responses were compared. Then we divided patients into two groups according to the carcinoembryonic antigen (CEA) clearance pattern after chemoradiation to explore risk factors that might predict the tumor regression response.

Results: Of 120 LARC patients, 34 (28.3%) exhibited poor regression. Stratified analysis by tumor response showed that patients with poor response to TNT were more likely to obtain elevated CEA during the course of TNT (all P < 0.05). For those with elevated pretreatment CEA, fewer patients with poor response obtained normal CEA after chemoradiation (13.6% vs. 72.7%, P < 0.001). Besides, less patients' CEA levels in the poor response group decreased by greater than 50% after chemoradiation when compared with that in the good response group (18.2% vs. 60.6%, P = 0.002). Stratified analysis by CEA clearance pattern after chemoradiation showed patients who obtained an elevated pretreatment CEA and decreased by less than 50% after chemoradiation were more likely to have poor response to TNT compared to others (76.2% vs. 18.2%, P < 0.001). Logistic multivariate analysis revealed that cN2 (95% CI 1.553-16.448), larger tumors (95% CI 2.250-21.428) and CEA clearance pattern after chemoradiation (95% CI 1.062-66.992) were independent risk factors for poor tumor regression response.

Conclusion: Approximately one-fourth of LARC patients with TNT achieved a poor regression response. Here, cN2, larger tumor size before treatment and elevated CEA levels were considered predictive features of a poor response. Active surveillance of CEA levels during the TNT course are potentially important, and CEA levels after chemoradiation might have important implications for the tumor response to TNT.

Keywords: carcinoembryonic antigen; locally advanced rectal cancer; risk factors; total neoadjuvant therapy; tumor regression response.